UPA IUS
Alternative Name: Ulipristal acetate (UPA) Intrauterine System (IUS)
Description: UPA is a selective progesterone receptor modulator, released via an intrauterine system.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Intrauterine
Duration Type: Long-acting
Duration: 3 years
Active Pharmaceutical Ingredient (API): - ulipristal acetate
- ulipristal acetate
Inactive material: elastomer
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: HRA Pharma, Population Council
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase I
Began discovery in: 2013
Active Development: Yes
Status Details: - A proof-of concept phase I clinical trial is ongoing.
- A proof-of concept phase I clinical trial is ongoing.
Additional Information
References: HRA Pharma website: http://www.hra-pharma.com/
Population Council website: www.popcouncil.org/about/product-licensing
Clinicaltrials.gov Identified NCT03230539
Brenner RM, Slayden OD, et al. (2010) Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception. 81(4):336-42.
HRA Pharma website: http://www.hra-pharma.com/
Population Council website: www.popcouncil.org/about/product-licensing
Clinicaltrials.gov Identified NCT03230539
Brenner RM, Slayden OD, et al. (2010) Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception. 81(4):336-42.